.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,395,754

« Back to Dashboard

Details for Patent: 6,395,754

Title: Substituted 2-(2,6-dioxopiperidin-3-yl)- phthalimides and 1-oxoisoindolines and method of reducing TNF.alpha. levels
Abstract:Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines reduce the levels of TNF.alpha. in a mammal. A typical embodiment is 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline.
Inventor(s): Muller; George W. (Bridgewater, NJ), Stirling; David I. (Branchburg, NJ), Chen; Roger Shen-Chu (Edison, NJ)
Assignee: Celgene Corporation, et al. (Warren, NJ)
Filing Date:Feb 22, 2000
Application Number:09/445,002
Claims:1. A 2,6-dioxopiperidine selected from the group consisting of (a) a compound of the formula: ##STR6##

in which:

one of X and Y is C.dbd.O and the other of X and Y is C.dbd.O or CH.sub.2 ;

R.sup.6 is hydrogen, alkyl of 1 to 8 carbon atoms, benzyl, chloro, or fluoro;

R.sup.7 is m-phenylene, p-phenylene or --(C.sub.n H.sub.2n)-- in which n has a value of 0 to 4;

each of R.sup.8 and R.sup.9 taken independently of the other is hydrogen or alkyl of 1 to 8 carbon atoms, or R.sup.8 and R.sup.9 taken together are tetramethylene, pentamethylene, hexamethylene, or --CH.sub.2 CH.sub.2 X.sup.1 CH.sub.2 CH.sub.2 -- in which X.sup.1 is --O--, --S-- or --NH--; and,

R.sup.10 is hydrogen, alkyl of 1 to 8 carbon atoms, or phenyl; and,

(b) the acid addition salts of said compounds which contain a nitrogen atom capable of being protonated.

2. A compound according to claim 1 wherein R.sup.6 is hydrogen.

3. A compound according to claim 2 wherein R.sup.7 is --(C.sub.n H.sub.2n)-- and n has a value of 0 to 4.

4. A compound according to claim 1 wherein R.sup.6 is alkyl of 1 to 8 carbon atoms.

5. A compound according to claim 1 wherein R.sup.6 is methyl.

6. A compound according to claim 5 wherein R.sup.7 is --(C.sub.n H.sub.2n)-- and n has a value of 0 to 4.

7. A compound according to claim 1 wherein R.sup.6 is ethyl.

8. A compound according to claim 7 wherein R.sup.7 is --(C.sub.n H.sub.2n)-- and n has a value of 0 to 4.

9. A compound according to claim 1 wherein R.sup.6 is propyl.

10. A compound according to claim 9 wherein R.sup.7 is --(C.sub.n H.sub.2n)-- and n has a value of 0 to 4.

11. A pharmaceutical composition comprising a quantity of a compound according to claim 1 sufficient upon administration in a single or multiple dose regimen to reduce levels of TNF.alpha. in a mammal in combination with a carrier.

12. The method of reducing undesirable levels of TNF.alpha. in a mammal which comprises administering thereto an effective amount of a compound according to claim 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc